drugset / Trial / NCT02561117

Once Daily Metronidazole for Perforated Appendicitis

NCT02561117 ↗

Phase 4 Withdrawn Ahmed Nasr
RandomizedSingle-groupQuadruple-blindTreatment

Summary

The objective of this study is to determine whether administering once-daily doses of metronidazole, an intravenous (IV) antibiotic used to prevent infection in perforated appendicitis, is as effective in children as delivering it in the standard method of once every eight hours. Reducing the frequency of administration has the potential of decreasing personnel time and healthcare cost and increasing the lifespan of the IV line. To determine the effectiveness once-daily administration, a randomized controlled trial (RCT) will be conducted to compare outcomes between the two treatment schedules. We will recruit 100 patients (50 per treatment) aged 5-18 being surgically treated for perforated appendicitis at the Children's Hospital of Eastern Ontario, who will be randomly assigned to one of the two treatment schedules. To compare the efficacy of the treatments, outcomes such as duration of hospital stay and theoretical cost will be measured and analyzed using statistical tests.

Timeline

Start
2019-01
Primary completion
2021-01
Completion
2022-01

Outcome

Outcome not reported

Stopped (Business): “Lack of funding”

Drugs

EvaluationDrugModalityDoseRoute
Subject Metronidazole Small molecule — Intravenous

Indications